< 1 minute read
Oct. 1, 2021

leriglitazone

oral PPARγ agonist for CNS diseases Ph. II and III ongoing for AMN and cALD one of the metabolites of pioglitazone Science Translational Medicine Minoryx Therapeutics S.L., Barcelona, ES

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in